| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
E6130 targets CX3CR1 (CX3C chemokine receptor 1), the receptor for the chemokine fractalkine (CX3CL1). It acts as a highly selective modulator of this receptor, inhibiting fractalkine-induced chemotaxis and down-regulating CX3CR1 expression on NK cell surfaces. The compound exhibits both antagonistic and modulatory activities at the receptor.
|
|---|---|
| ln Vitro |
E6130 is an oral, highly selective, and active modulator of CX3CR1 that inhibits the chemotaxis of human peripheral blood natural killer cells elicited by fractalkine (IC50, 4.9 nM) and downregulates the expression of CX3CR1 on the surface of CD56+ NK cells (EC50, 5.2 nM). In addition, E6130 demonstrated agonistic action towards GTPγS binding (EC50 = 133 nM) and β-arrestin recruitment (EC50 = 2.4 μM) via CX3CR1 in membranes expressing CX3CR1 [1].
In vitro, E6130 inhibits fractalkine-induced chemotaxis of human peripheral blood NK cells with an IC₅0 of 4.9 nM. It down-regulates CX3CR1 on the cell surface of CD56+ NK cells with an EC₅0 of 5.2 nM. These activities demonstrate the compound's potent and selective modulation of CX3CR1 signaling. The compound is orally active and highly selective for CX3CR1. |
| ln Vivo |
In a mouse model of colitis created by oxazolone and a mouse model of colitis caused by CD4+ CD45RBhigh T cell transfer, E6130 (10 or 30 mg/kg, orally) decreases several parameters associated with inflammatory bowel disease [1].
In vivo activity data for E6130 are not extensively documented in the public domain. As an orally active CX3CR1 modulator, the compound is expected to show efficacy in inflammatory disease models, particularly inflammatory bowel disease. The compound's oral bioavailability and selective receptor modulation make it a promising candidate for further in vivo studies in IBD and other inflammatory conditions. |
| Enzyme Assay |
The in vitro receptor binding and functional assay for CX3CR1 uses cells expressing the receptor (such as human peripheral blood NK cells or transfected cell lines). Chemotaxis assays are performed using Boyden chambers or microfluidic devices, with fractalkine as the chemoattractant. Cells are pre-incubated with varying concentrations of E6130, and the number of cells migrating toward fractalkine is quantified. IC₅0 values are calculated from dose-response curves. Receptor down-regulation is assessed by flow cytometry using anti-CX3CR1 antibodies.
|
| Cell Assay |
For in vitro cell-based assays, human peripheral blood NK cells are isolated and cultured. Cells are treated with E6130 at various concentrations, and fractalkine-induced chemotaxis is measured. CX3CR1 cell surface expression is quantified by flow cytometry after treatment. CD56+ NK cells are identified by surface marker staining. Experiments are typically performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
In vivo animal studies for E6130 would typically involve mouse models of inflammatory bowel disease (such as DSS-induced colitis or TNBS-induced colitis). The compound is administered orally at various doses. Disease severity is assessed by body weight loss, stool consistency, and histological analysis of colon tissue. Inflammatory cytokine levels are measured in colon tissue or serum. Receptor engagement is confirmed by assessing CX3CR1 expression on immune cells.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of E6130 indicate that it is orally active and bioavailable. The compound is a highly selective CX3CR1 modulator suitable for oral administration. Detailed PK parameters (half-life, Cmax, AUC, bioavailability) are not extensively documented in the available literature. The compound is typically formulated for oral administration in research settings. Further PK studies would be needed to fully characterize its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for E6130 are not well characterized in the public domain. As a research chemical, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications. CX3CR1 modulators as a class may have potential effects on immune cell trafficking and inflammatory responses. Comprehensive toxicity profiling would be required for therapeutic development.
|
| References | |
| Additional Infomation |
E6130 (CAS# 1427058-33-0) is an orally active, highly selective CX3CR1 modulator. It inhibits fractalkine-induced NK cell chemotaxis (IC₅0 = 4.9 nM) and down-regulates CX3CR1 on NK cells (EC₅0 = 5.2 nM). The compound has potential utility in inflammatory bowel disease research. It is not approved for clinical use and is strictly for laboratory research purposes.
|
| Molecular Formula |
C28H37CLF3N3O3
|
|---|---|
| Molecular Weight |
556.059897184372
|
| Exact Mass |
555.247
|
| CAS # |
1427058-33-0
|
| PubChem CID |
71293692
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
38
|
| Complexity |
877
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
ClC1=CC=CC(C(F)(F)F)=C1CN1CC(C)[C@@](C(NC2CCN(CC3=CCCCC3)CC2)=O)(CC(=O)O)C1
|
| InChi Key |
JTJKDYLEMNXXER-UZTOHYMASA-N
|
| InChi Code |
InChI=1S/C28H37ClF3N3O3/c1-19-15-35(17-22-23(28(30,31)32)8-5-9-24(22)29)18-27(19,14-25(36)37)26(38)33-21-10-12-34(13-11-21)16-20-6-3-2-4-7-20/h5-6,8-9,19,21H,2-4,7,10-18H2,1H3,(H,33,38)(H,36,37)/t19-,27+/m0/s1
|
| Chemical Name |
2-[(3S,4R)-1-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]-3-[[1-(cyclohexen-1-ylmethyl)piperidin-4-yl]carbamoyl]-4-methylpyrrolidin-3-yl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~449.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7984 mL | 8.9918 mL | 17.9837 mL | |
| 5 mM | 0.3597 mL | 1.7984 mL | 3.5967 mL | |
| 10 mM | 0.1798 mL | 0.8992 mL | 1.7984 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
